2
|
Kuehn HS, Nunes-Santos CJ, Rosenzweig SD. Germline IKZF1 mutations and their impact on immunity: IKAROS-associated diseases and pathophysiology. Expert Rev Clin Immunol 2021; 17:407-416. [PMID: 33691560 PMCID: PMC8091572 DOI: 10.1080/1744666x.2021.1901582] [Citation(s) in RCA: 21] [Impact Index Per Article: 5.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2021] [Accepted: 03/08/2021] [Indexed: 10/21/2022]
Abstract
Introduction: The transcription factor IKAROS and IKAROS family members are critical for the development of lymphocyte and other blood cell lineages. Germline heterozygous IKZF1 mutations have been described in primary immunodeficiency as well as in human hematologic malignancies, affecting both B and T cells. Depending on the allelic variants of IKZF1 mutations (haploinsufficiency and dominant negative) clinical phenotypes vary from bacterial, viral, or fungal infection to autoimmune disease and malignancy.Areas covered: In this review, the authors provide an overview of genotype-phenotype correlation and clinical manifestations in patients with IKZF1 mutations. The importance of accurate diagnosis and monitoring immunological changes is also discussed for the management of these complex and rare diseases. IKZF1/IKAROS, immunodeficiency, and CVID were used as the search terms in PubMed and Google Scholar.Expert opinion: Over the past 5 years both genetic and molecular studies have unveiled surprisingly diverse roles of IKZF1 mutations in primary immunodeficiency. While an increasing number of novel IKZF1 variants are being reported, limited, and complex laboratory testing is necessary to verify the mutation's pathogenicity. Therefore, the combination of understanding mechanistic concepts and clinical and immunological follow-up is necessary to increase our knowledge of IKAROS-associated diseases.
Collapse
Affiliation(s)
- Hye Sun Kuehn
- Immunology Service, Department of Laboratory Medicine, National Institutes of Health (NIH) Clinical Center, Bethesda, Md
| | - Cristiane J Nunes-Santos
- Immunology Service, Department of Laboratory Medicine, National Institutes of Health (NIH) Clinical Center, Bethesda, Md
| | - Sergio D. Rosenzweig
- Immunology Service, Department of Laboratory Medicine, National Institutes of Health (NIH) Clinical Center, Bethesda, Md
| |
Collapse
|
3
|
Pozzesi N, Fierabracci A, Thuy TT, Martelli MP, Liberati AM, Ayroldi E, Riccardi C, Delfino DV. Pharmacological modulation of caspase-8 in thymus-related medical conditions. J Pharmacol Exp Ther 2014; 351:18-24. [PMID: 25060674 DOI: 10.1124/jpet.114.216572] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2024] Open
Abstract
The thymus is a lymphoid organ that governs the development of a diverse T-cell repertoire capable of defending against nonself-antigens and avoiding autoimmunity. However, the thymus can also succumb to different diseases. Hypertrophic diseases, such as thymomas, are typically associated with impairment of negative selection, which leads to autoimmune disease, or disruption of positive selection, which results in immunodeficiency. Hypotrophic diseases of the thymus can manifest during acute infections, cancer, allogeneic bone marrow transplantation, or with aging. This condition leads to decreased immune function and can be treated by either replacing lost thymic tissue or by preventing thymic tissue death. Studies have demonstrated the critical role of caspase-8 in regulating apoptosis in the thymus. In this review, we discuss how pharmacological activation and inhibition of caspase-8 can be used to treat hypertrophic and hypotrophic diseases of the thymus, respectively, to improve its function.
Collapse
Affiliation(s)
- Nicola Pozzesi
- Foligno Nurse School, Department of Medicine (N.P.), Section of Hematology (M.P.M.), Section of Pharmacology (E.A., C.R., D.V.D.), Department of Medicine, Section of Onco-Hematology, Hospital S. Maria, Terni, Department of Surgery (A.M.L.), University of Perugia, Perugia, Italy; Autoimmunity Laboratory, Immunology and Pharmacotherapy Area, Bambin Gesù Children's Hospital IRCCS, Rome, Italy (A.F.); and Institute of Chemistry, Vietnam Academy of Science and Technology, Cau Giay, Hanoi, Vietnam (T.T.T.)
| | - Alessandra Fierabracci
- Foligno Nurse School, Department of Medicine (N.P.), Section of Hematology (M.P.M.), Section of Pharmacology (E.A., C.R., D.V.D.), Department of Medicine, Section of Onco-Hematology, Hospital S. Maria, Terni, Department of Surgery (A.M.L.), University of Perugia, Perugia, Italy; Autoimmunity Laboratory, Immunology and Pharmacotherapy Area, Bambin Gesù Children's Hospital IRCCS, Rome, Italy (A.F.); and Institute of Chemistry, Vietnam Academy of Science and Technology, Cau Giay, Hanoi, Vietnam (T.T.T.)
| | - Trinh Thy Thuy
- Foligno Nurse School, Department of Medicine (N.P.), Section of Hematology (M.P.M.), Section of Pharmacology (E.A., C.R., D.V.D.), Department of Medicine, Section of Onco-Hematology, Hospital S. Maria, Terni, Department of Surgery (A.M.L.), University of Perugia, Perugia, Italy; Autoimmunity Laboratory, Immunology and Pharmacotherapy Area, Bambin Gesù Children's Hospital IRCCS, Rome, Italy (A.F.); and Institute of Chemistry, Vietnam Academy of Science and Technology, Cau Giay, Hanoi, Vietnam (T.T.T.)
| | - Maria Paola Martelli
- Foligno Nurse School, Department of Medicine (N.P.), Section of Hematology (M.P.M.), Section of Pharmacology (E.A., C.R., D.V.D.), Department of Medicine, Section of Onco-Hematology, Hospital S. Maria, Terni, Department of Surgery (A.M.L.), University of Perugia, Perugia, Italy; Autoimmunity Laboratory, Immunology and Pharmacotherapy Area, Bambin Gesù Children's Hospital IRCCS, Rome, Italy (A.F.); and Institute of Chemistry, Vietnam Academy of Science and Technology, Cau Giay, Hanoi, Vietnam (T.T.T.)
| | - Anna Marina Liberati
- Foligno Nurse School, Department of Medicine (N.P.), Section of Hematology (M.P.M.), Section of Pharmacology (E.A., C.R., D.V.D.), Department of Medicine, Section of Onco-Hematology, Hospital S. Maria, Terni, Department of Surgery (A.M.L.), University of Perugia, Perugia, Italy; Autoimmunity Laboratory, Immunology and Pharmacotherapy Area, Bambin Gesù Children's Hospital IRCCS, Rome, Italy (A.F.); and Institute of Chemistry, Vietnam Academy of Science and Technology, Cau Giay, Hanoi, Vietnam (T.T.T.)
| | - Emira Ayroldi
- Foligno Nurse School, Department of Medicine (N.P.), Section of Hematology (M.P.M.), Section of Pharmacology (E.A., C.R., D.V.D.), Department of Medicine, Section of Onco-Hematology, Hospital S. Maria, Terni, Department of Surgery (A.M.L.), University of Perugia, Perugia, Italy; Autoimmunity Laboratory, Immunology and Pharmacotherapy Area, Bambin Gesù Children's Hospital IRCCS, Rome, Italy (A.F.); and Institute of Chemistry, Vietnam Academy of Science and Technology, Cau Giay, Hanoi, Vietnam (T.T.T.)
| | - Carlo Riccardi
- Foligno Nurse School, Department of Medicine (N.P.), Section of Hematology (M.P.M.), Section of Pharmacology (E.A., C.R., D.V.D.), Department of Medicine, Section of Onco-Hematology, Hospital S. Maria, Terni, Department of Surgery (A.M.L.), University of Perugia, Perugia, Italy; Autoimmunity Laboratory, Immunology and Pharmacotherapy Area, Bambin Gesù Children's Hospital IRCCS, Rome, Italy (A.F.); and Institute of Chemistry, Vietnam Academy of Science and Technology, Cau Giay, Hanoi, Vietnam (T.T.T.)
| | - Domenico V Delfino
- Foligno Nurse School, Department of Medicine (N.P.), Section of Hematology (M.P.M.), Section of Pharmacology (E.A., C.R., D.V.D.), Department of Medicine, Section of Onco-Hematology, Hospital S. Maria, Terni, Department of Surgery (A.M.L.), University of Perugia, Perugia, Italy; Autoimmunity Laboratory, Immunology and Pharmacotherapy Area, Bambin Gesù Children's Hospital IRCCS, Rome, Italy (A.F.); and Institute of Chemistry, Vietnam Academy of Science and Technology, Cau Giay, Hanoi, Vietnam (T.T.T.)
| |
Collapse
|
4
|
Torres LC, Soares DCDQ, Kulikowski LD, Franco JF, Kim CA. NK and B cell deficiency in a MPS type II family with novel mutation in the IDS gene. Clin Immunol 2014; 154:100-4. [PMID: 25038527 DOI: 10.1016/j.clim.2014.07.001] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/02/2013] [Revised: 06/09/2014] [Accepted: 07/04/2014] [Indexed: 11/16/2022]
Abstract
The mucopolysaccharidoses (MPSs) are a group of rare, inherited lysosomal storage disorders that are clinically characterized by abnormalities in multiple organ systems and reduced life expectancy. Whereas the lysosome is essential to the functioning of the immune system, some authors suggest that the MPS patients have abnormalities in the immune system similar to the patients with primary immunodeficiency. In this study, we evaluated 8 male MPS type II patients of the same family with novel mutation in the IDS gene. We found in this MPS family a quantitative deficiency of NK and B cells with normal values of IgG, IgM and IgA serum antibodies and normal response to polysaccharide antigens. Interestingly, abnormalities found in these patients were not observed in other MPS patients, suggesting that the type of mutation found in the IDS gene can be implicated in the immunodeficiency.
Collapse
Affiliation(s)
- Leuridan Cavalcante Torres
- Translational Research Laboratory Prof. C. A. Hart, Instituto de Medicina Integral Prof. Fernando Figueira (IMIP), Recife, Brazil; Medical Investigation Laboratory (LIM 36), Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo (USP), São Paulo, Brazil.
| | - Diogo Cordeiro de Queiroz Soares
- Translational Research Laboratory Prof. C. A. Hart, Instituto de Medicina Integral Prof. Fernando Figueira (IMIP), Recife, Brazil; Medical Genetics Unit, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo (USP), São Paulo, Brazil
| | - Leslie Domenici Kulikowski
- Department of Pathology, Citogenomics Laboratory (LIM 03), Universidade de São Paulo (USP), São Paulo, Brazil
| | - Jose Francisco Franco
- Medical Genetics Unit, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo (USP), São Paulo, Brazil
| | - Chong Ae Kim
- Medical Genetics Unit, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo (USP), São Paulo, Brazil
| |
Collapse
|
6
|
Sun SL, Horino S, Itoh-Nakadai A, Kawabe T, Asao A, Takahashi T, So T, Funayama R, Kondo M, Saitsu H, Matsumoto N, Nakayama K, Ishii N. Y chromosome-linked B and NK cell deficiency in mice. THE JOURNAL OF IMMUNOLOGY 2013; 190:6209-20. [PMID: 23690476 DOI: 10.4049/jimmunol.1300303] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/28/2023]
Abstract
There are no primary immunodeficiency diseases linked to the Y chromosome, because the Y chromosome does not contain any vital genes. We have established a novel mouse strain in which all males lack B and NK cells and have Peyer's patch defects. By 10 wk of age, 100% of the males had evident immunodeficiencies. Mating these immunodeficient males with wild-type females on two different genetic backgrounds for several generations demonstrated that the immunodeficiency is linked to the Y chromosome and is inherited in a Mendelian fashion. Although multicolor fluorescence in situ hybridization analysis showed that the Y chromosome in the mutant male mice was one third shorter than that in wild-type males, exome sequencing did not identify any significant gene mutations. The precise molecular mechanisms are still unknown. Bone marrow chimeric analyses demonstrated that an intrinsic abnormality in bone marrow hematopoietic cells causes the B and NK cell defects. Interestingly, fetal liver cells transplanted from the mutant male mice reconstituted B and NK cells in lymphocyte-deficient Il2rg(-/-) recipient mice, whereas adult bone marrow transplants did not. Transducing the EBF gene, a master transcription factor for B cell development, into mutant hematopoietic progenitor cells rescued B cell but not NK cell development both in vitro and in vivo. These Y chromosome-linked immunodeficient mice, which have preferential B and NK cell defects, may be a useful model of lymphocyte development.
Collapse
Affiliation(s)
- Shu-lan Sun
- Department of Microbiology and Immunology, Tohoku University Graduate School of Medicine, Sendai 980-8575, Japan
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|